Pipeline

Ivaltinostat

Indication
Treatment of lung inflammation and fibrosis caused by COVID-19
Development stage
Preparing for a phase 2 clinical trial in the U.S. for moderate and severe COVID-19 patients

Ivaltinostat

Development of COVID-19 treatment plans

Acute Respiratory Distress Syndrome (ARDS) Is the leading cause of death for COVID-19 patients
ARDS induces acute pulmonary inflammation and fibrosis due to the disruption of immune homeostatis by continuously inducing an overactive state of the immune system
Anti-inflammatory and anti-fibrotic drugs are being developed worldwide for the treatment of COVID-19.

Ivaltinostat's competitive advantage

01

Efficacy has been verified in various animal models, including ARDS models
02

Limited safety concerns based on results from a Phase 1 clinical study in healthy adults
03

Completed development of oral formulation of ivaltinostat for ease of use

Ivaltinostat's mechanism of action

Inhibition of key mechanisms of inflammatory cytokine production (reduction of angiotensinogen expression)
Anti-inflammatory function in acute lung injury mouse model (reduction of inflammatory cytokines IL-6, IL-1β, TNF-α expression)
Anti-inflammatory function in flu virus infection mouse model (reduction of inflammatory cytokines TNF-α and IFN-γ expression)
Suppression of immune hypersensitivity reaction through regulation of neutrophil count
Inhibition of the expression of fibrotic proteins (Collagen-1, Vimentin, Fibronectin)

References

1.
Yoon, G.E. et al. Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production. Schmiedebergs Arch. Pharmacol. 393, 491-500 (2020).
2.
Kim, Y.S. et al. The anti-fibrotic effects of CG-745, an HDAC inhibitor, in bleomycin and PHMG-induced mouse models. Molecules 24, 2792 (2019).

타이틀